Business Context and Reporting Period
This Form 6-K filing by CollPlant Biotechnologies Ltd. covers the month of August 2026. The primary event reported is the entry into a Share Purchase Agreement on August 29, 2026, to acquire 100% of the issued and outstanding share capital of LightSolver Ltd., a company operating in the photonics market. The acquisition is expected to close in the week following the agreement date, subject to customary conditions.
Key Financial Metrics and Transaction Structure
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels for the reporting period. Instead, it details the financial structure of the LightSolver acquisition:
- Consideration Securities: The Company agreed to issue 3,734,476 ordinary shares (representing 19.7% of pre-transaction outstanding shares), pre-funded warrants for 6,134,363 shares, and milestone-based warrants for up to 224,078,345 shares.
- Warrant Pricing: The purchase price for Pre-Funded Warrants and Milestone Warrants is $0.00001 per share.
- Rollover Options: Options to purchase 2,261,966 shares were issued to certain LightSolver option holders.
- Outstanding Liabilities: A $2.0 million Simple Agreement for Future Equity (SAFE) from LightSolver remains outstanding and may result in future dilution.
- Advisor Compensation: Finder warrants for 2,000,000 shares at $0.36/share were issued to H.C. Wainwright & Co., LLC. Rodman & Renshaw, LLC and another advisor are to receive shares, pre-funded warrants, and milestone warrants, subject to shareholder approval.
Material Changes and Strategic Shifts
The acquisition represents a material strategic shift, expanding CollPlant's operations into the photonics market while maintaining its existing regenerative and aesthetic medicine business. Key changes include:
- Board Composition: Dr. Ruti Ben Shlomi, CEO and Co-Founder of LightSolver, was appointed to the Company's board of directors effective at closing.
- Executive Retention: Dr. Ben Shlomi and LightSolver's CTO, Chene Tradonsky, are required to sign continuation engagement agreements for at least 36 months.
- Asset Monetization: The agreement permits the Company to monetize certain regenerative and aesthetic medicine assets post-closing, with 20% of net proceeds payable to designated officers.
- Dilution Risk: The transaction involves significant potential dilution through the issuance of Closing Shares, Pre-Funded Warrants, and Milestone Warrants, though an "Equity Blocker" mechanism limits issuance under Nasdaq Listing Rule 5635 until shareholder approval is obtained.
Guidance, Outlook, and Risks
Management intends to continue evaluating and managing its existing business while integrating LightSolver. The Company plans to file a registration statement on Form F-1 or F-3 within 75 days of closing to cover the resale of securities issued in the transaction.
Risks and Contingencies:
- Closing Conditions: The transaction is subject to customary closing conditions; failure to satisfy these could prevent the acquisition.
- Shareholder Approval: Issuance of shares upon exercise of Pre-Funded Warrants, Milestone Warrants, and advisor securities is contingent on shareholder approval to comply with Nasdaq rules.
- Forward-Looking Statements: The filing contains forward-looking statements regarding the expected closing and future operations, which are subject to risks and uncertainties.
- SAFE Agreement: The unconverted $2.0 million SAFE may lead to future dilution of the Company's ownership in LightSolver.
Investor Verification Checklist
- Verify the exact closing date and confirmation that all customary closing conditions have been satisfied.
- Monitor the timeline for the filing and effectiveness of the Form F-1 or F-3 registration statement for the resale of acquisition securities.
- Track the status of shareholder approval required for the issuance of shares under the Equity Blocker mechanism and for advisor compensation.
- Review the specific operational milestones required to exercise the 224,078,345 Milestone Warrants.
- Assess the potential impact of the outstanding $2.0 million SAFE on future capital structure and ownership dilution.